Table I.
Clinical characteristics of 12 patients with autoimmune disease and sinus tachycardia.
| Concomitant medication | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. | Gender | Age (years) | IRD | NYHA | Mechanical ventilation | Disease activity | Loop diuretics | β-blockers | Ivabradine | Glucocorticoids | Immunosuppressants | |
| 1 | F | 34 | SLE | III | No | SLEDAI, 10; ESR, 20 mm; hsCRP, 0.32 mg/l | Furosemide 80 mg/d | Metoprolol 12.5 mg/d | 5 mg/d | MP 24 mg/d | No | |
| 2 | M | 29 | SLE/secondary APS | IV | No | SLEDAI, 2; ESR, 31 mm; hsCRP, 1.52 mg/l | Torasemide 5 mg/d | Metoprolol 37.5 mg/d | 5 mg/d | No | No | |
| 3 | F | 17 | GPA | IV | Yes | ESR, 34 mm; hsCRP, 55.01 mg/l | Furosemide 20 mg/d | No | 5 mg/d | MP 80 mg/d | No | |
| 4 | F | 16 | PM/DM | IV | No | ESR, 6 mm; hsCRP, 1.10 mg/l | Torasemide 20 mg/d | Metoprolol 50 mg/d | 5 mg/d | MP 80 mg/d | CTX 200 mg/w | |
| 5 | F | 33 | SLE | III | No | SLEDAI, 4; ESR, 16 mm; hsCRP, 5.12 mg/l | Furosemide 40 mg/d | Metoprolol 25 mg/d | 5 mg/d | No | No | |
| 6 | F | 62 | SLE | IV | Yes | SLEDAI, 4; ESR, 43 mm; hsCRP, 44.53 mg/l | Furosemide 100 mg/d | Metoprolol 12.5 mg/d | 5–15 mg/d | Hydrocortisone 150 mg/d | No | |
| 7 | F | 34 | SLE | IV | Yes | SLEDAI, 10 | Furosemide 40 mg/d | No | 5 mg/d | MP 80 mg/d | No | |
| 8 | F | 36 | SLE | III | No | SLEDAI: 4 ESR, 21 mm; hsCRP, 2.51 mg/l | Furosemide 40 mg/d | Carvedilol 50 mg/d | 5 mg/d | MP 40 mg/d | No | |
| 9 | F | 32 | SLE | III | No | SLEDAI, 7; ESR, 3 mm; hsCRP, 0.13 mg/l | No | Metoprolol 25 mg/d | 5–10 mg/d | MP 24 mg/d | CTX 400 mg/w | |
| 10 | F | 48 | GPA | IV | Yes | ESR, 8 mm; hsCRP, 180.64 mg/l | Furosemide 80 mg/d | Metoprolol 25 mg/d | 5 mg/d | MP pulse + 80 mg/d | CTX 400 mg/w | |
| 11 | F | 21 | PM/DM | III | No | ESR, 86 mm; hsCRP, 1.47 mg/l; | No | Metoprolol 25 mg/d | 5–10 mg/d | MP 40 mg/d | Tacrolimus 2–3 mg/d | |
| 12 | M | 43 | PM/DM | III | No | ERS, 25 mm; hsCRP, 0.95 mg/l | Furosemide 20 mg/d | Metoprolol 25 mg/d | 5–10 mg/d | Prednisone 60 mg/d | CTX 400 mg/w | |
SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome; IRD, inflammatory rheumatic disease; GPA, granulomatosis with polyangiitis; PM/DM, polymyositis/dermatomyositis; SLEDAI, SLE disease activity index; ESR, erythrocyte sedimentation rate (normal range, <15mm); hsCRP, high-sensitivity C-reactive protein (normal range: <3 mg/l); MP, methylprednisolone; CTX, cyclophosphamide; d, day; w, week; M, male; F, female; NYHA, New York Heart Association.